OncoMatch/Clinical Trials/NCT05954442
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Is NCT05954442 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Everolimus and Investigator's Choice of Chemotherapy for triple negative breast cancer.
Treatment: Everolimus · Investigator's Choice of Chemotherapy — The goal of this clinical trial is to evaluate the efficacy of investigator's choice of chemotherapy, either alone or in combination with everolimus, in treating patients with locally recurrent inoperable or metastatic triple-negative breast cancer, luminal androgen receptor (LAR) subtype with PI3K/AKT/mTOR (PAM) pathway mutation, as the first-line treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer
Cannot have received: targeted therapy
No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer
Cannot have received: radiotherapy
Exception: within 3 weeks prior to study initiation
Patients have not received radiotherapy, endocrine therapy, molecular targeted therapy, or surgery within 3 weeks prior to study initiation
Cannot have received: endocrine therapy
Exception: within 3 weeks prior to study initiation
Patients have not received radiotherapy, endocrine therapy, molecular targeted therapy, or surgery within 3 weeks prior to study initiation
Cannot have received: molecular targeted therapy
Exception: within 3 weeks prior to study initiation
Patients have not received radiotherapy, endocrine therapy, molecular targeted therapy, or surgery within 3 weeks prior to study initiation
Cannot have received: surgery
Exception: within 3 weeks prior to study initiation
Patients have not received radiotherapy, endocrine therapy, molecular targeted therapy, or surgery within 3 weeks prior to study initiation
Lab requirements
Blood counts
HB≥90g/L (no blood transfusion within 14 days); ANC≥1.5×10^9/L; PLT≥75×10^9/L
Kidney function
Serum Cr ≤1×ULN, endogenous creatinine clearance > 50ml/min (Cockcroft-Gault formula)
Liver function
TBIL≤1.5× ULN; ALT and AST≤3 x ULN; In case of liver metastasis, ALT and AST≤5×ULN
The functions of the main organs are basically normal, and the following conditions are met: Blood routine examination standards should meet: HB≥90g/L (no blood transfusion within 14 days); ANC≥1.5×109/L; PLT≥75×109/L; Biochemical examination shall meet the following standards: TBIL≤1.5× ULN; ALT and AST≤3 x ULN; In case of liver metastasis, ALT and AST≤5×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance > 50ml/min (Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify